To the Editor-Described are the first reported cases of osteomyelitis due to linezolid-resistant Staphylococcus epidermidis.
Case 1 was a 73-year-old woman with severe peripheral vascular disease and a recent diagnosis 6 months prior to admission of polymicrobial osteomyelitis of the left calcaneus, which had required multiple heel debridements, partial calcanectomy, and a skin grafting procedure. Linezolid and piperacillintazobactam were administered throughout her surgical course and for 6 weeks following her skin graft, at which time she was switched to linezolid monotherapy (linezolid was eventually discontinued 2 weeks prior to admission).
She was admitted after a fall at home and was found to have purulent drainage from her left lower extremity graft with exposed bone. Imipenem-cilastatin was started empirically, and linezolid was added 2 days later. A deep wound swab obtained 2 days after admission isolated a coagulase-negative staphylococcus species that was not subjected to further laboratory testing. Surgical intervention was delayed due to initial patient refusal but was ultimately performed 2 weeks later. Bone cultures obtained intraoperatively isolated linezolid-resistant S. epidermidis ( Table 1 ). The patient was eventually treated successfully with intravenous vancomycin and extensive plastic surgery.
Case 2 was a 55-year-old man with chronically infected patellar hardware and associated left patellar osteomyelitis. He had been receiving linezolid for 6 weeks prior to admission from an outside prescriber following his most recent patellar debridement. He presented after a fall at his long-term acute care facility and was found to have a swollen left knee with purulent drainage. Culture of this drainage grew methicillin-resistant S. epidermidis susceptible to linezolid (minimum inhibitory concentration, #2 lg/mL). Bone cultures obtained during hardware removal 5 days later isolated 2 colony types of S. epidermidis: one that was linezolid susceptible and another that was linezolid resistant (Table 1) . Due to a reported allergy to vancomycin, the patient was transitioned to daptomycin. He underwent 5 additional debridements in the month following hardware removal, and the linezolidresistant S. epidermidis strain was isolated from each of 4 debridements in which cultures were obtained. After his surgical course was completed and his wound was closed, he received an additional 6 weeks of daptomycin therapy with successful suppression of his infection. These are the first reports of osteomyelitis due to linezolid-resistant S. epidermidis. As in similar cases of linezolid-resistant staphylococcal infections, both patients received prolonged courses of linezolid in the setting of inadequate surgical debridement prior to isolation of a linezolid-resistant organism [1] [2] [3] [4] [5] [6] [7] [8] [9] . Although a detailed molecular analysis could not be performed, the antimicrobial susceptibility profiles of each isolate were different, suggesting that linezolid resistance developed independently during therapy ( Table 1) . Because of the deep-seated nature of osteomyelitis, the inconsistent concentrations of linezolid achievable in infected bone [10] , and the frequency with which staphylococci cause osteomyelitis, we believe our experience could be replicated. The potential for Staphylococcus aureus to acquire linezolid resistance in a similar clinical setting is of particular concern. Linezolid should be reserved for patients failing or intolerant of conventional therapies for osteomyelitis.
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